| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2006 | EP1660067A1 Methods and materials for treating conditions associated with metabolic disorders |
| 05/31/2006 | EP1660066A1 Pharmaceutical composition comprising a combination of metformin and a statin |
| 05/31/2006 | EP1660065A2 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| 05/31/2006 | EP1660064A2 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| 05/31/2006 | EP1660063A1 Use of bicyclo [2.2.1] heptane derivatives for the preparation of neuroprotective pharmaceutical compositions |
| 05/31/2006 | EP1660062A1 Use of colipase-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity |
| 05/31/2006 | EP1660061A1 Use of n-chlorotaurine for treatment of oozing tissue deficiencies |
| 05/31/2006 | EP1660060A2 Pharmaceutical compositions for preventing breast and ovarian cancer |
| 05/31/2006 | EP1660059A1 Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars) |
| 05/31/2006 | EP1660058A2 The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| 05/31/2006 | EP1660057A2 Combination therapy for the treatment of ocular neovascular disorders |
| 05/31/2006 | EP1660055A1 Transdermal formulation comprising an opioid analgesic and an aloe composition |
| 05/31/2006 | EP1660054A1 Agent containing ergolin for transdermal application |
| 05/31/2006 | EP1660053A2 Skeletally targeted nanoparticles |
| 05/31/2006 | EP1660052A2 Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| 05/31/2006 | EP1660048A1 Method for deterring abuse of opioids by combination with non-release formulation of emetic |
| 05/31/2006 | EP1660046A1 Powder formulation comprising the cgrp antagonist 1- (n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine |
| 05/31/2006 | EP1660044A2 Composition comprising a zeolite compound for treatment of diseases |
| 05/31/2006 | EP1660043A2 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 05/31/2006 | EP1660040A1 In vivo targeting of dendritic cells |
| 05/31/2006 | EP1660039A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 05/31/2006 | EP1660038A1 Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| 05/31/2006 | EP1660037A2 Methods for administering aripiprazole |
| 05/31/2006 | EP1660035A2 Liquid compositions comprising formoterol |
| 05/31/2006 | EP1660029A2 Compositions containing topical active agents and pentylene glycol |
| 05/31/2006 | EP1660026A2 Treatment for cd5+ b cell lymphoma |
| 05/31/2006 | EP1660013A2 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 05/31/2006 | EP1660012A2 Cellular depolarization and regulation of matrix metalloproteinases |
| 05/31/2006 | EP1660011A2 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 05/31/2006 | EP1660009A2 Methods for the treatment of endometriosis |
| 05/31/2006 | EP1660007A2 Compositions for diabetes treatment and prophylaxis |
| 05/31/2006 | EP1660001A1 Crosslinking reagent for treating vertebral disc disorders |
| 05/31/2006 | EP1659970A1 Sytem and method for prevention of radiocontrast induced nephropathy |
| 05/31/2006 | EP1606233B1 Phospholipid esters of Clofarabin |
| 05/31/2006 | EP1585753B1 Novel semisynthetic macrolide antibiotics of the azalide series |
| 05/31/2006 | EP1558263B1 Prolonged release pharmaceutical composition |
| 05/31/2006 | EP1558240B1 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia |
| 05/31/2006 | EP1556356B1 Tetrahydroquinoline derivatives as crth2 antagonists |
| 05/31/2006 | EP1546123B1 Benzyl morpholine derivatives |
| 05/31/2006 | EP1485343A4 Amorphous hmg-coa reductase inhibitors of desired particle size |
| 05/31/2006 | EP1467737B1 Orally dispersible pharmaceutical piribedil composition |
| 05/31/2006 | EP1453512B1 Acetylene derivatives having mglur 5 antagonistic activity |
| 05/31/2006 | EP1448181B1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 05/31/2006 | EP1446122B1 Use of flibanserin in the treatment of sexual desire disorders |
| 05/31/2006 | EP1441716B1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions |
| 05/31/2006 | EP1420824B1 Sulfonated chlorines as photosensitizer |
| 05/31/2006 | EP1420644B1 Substituted propargylamines |
| 05/31/2006 | EP1413305B1 Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence |
| 05/31/2006 | EP1408960B1 Benz-indole and benzo-quinoline derivatives as prodrugs for tumour treatment |
| 05/31/2006 | EP1401821A4 Novel phenylalkyl diamine and amide analogs |
| 05/31/2006 | EP1392295B1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
| 05/31/2006 | EP1390356B1 Arylisoxazoline derivatives, method for production and use thereof as pesticides |
| 05/31/2006 | EP1368336B1 Thiophene substituted amine derivatives as glyt-1 inhibitors |
| 05/31/2006 | EP1363504B1 Process for the fractionation of cereal brans |
| 05/31/2006 | EP1352061B1 Method for inhibiting the expression of a target gene |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1343772B1 Thia- and oxazoles and their use as ppars activators |
| 05/31/2006 | EP1333845A4 Treatment of t cell disorders |
| 05/31/2006 | EP1328282B1 Efficient method for producing compositions enriched in anthocyanins |
| 05/31/2006 | EP1318997B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317449B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317444B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1315500A4 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 05/31/2006 | EP1313855B1 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 05/31/2006 | EP1296967B1 Benzothiazolyl ppar-gamma modulators |
| 05/31/2006 | EP1296931B1 Polyamine analogues as cytotoxic agents |
| 05/31/2006 | EP1294348B1 Skin preparation |
| 05/31/2006 | EP1272223B1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 05/31/2006 | EP1272156B1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials |
| 05/31/2006 | EP1270579B1 Process for producing camptothecin |
| 05/31/2006 | EP1270570B1 Amide compounds and use thereof |
| 05/31/2006 | EP1263525B1 Method for preparing colloidal particles in the form of nanocapsules |
| 05/31/2006 | EP1263467B1 Paste formulations comprising silica |
| 05/31/2006 | EP1248641B1 Use of emap ii receptor antagonist composition for treating pulmonary hypertension |
| 05/31/2006 | EP1246789B1 Methods of making optically pure (r)- and (s)- didesmethylsibutramine |
| 05/31/2006 | EP1242012A4 Improved transdermal contraceptive delivery system and process |
| 05/31/2006 | EP1235851B1 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/31/2006 | EP1221997A4 System and device for preventing restenosis in body vessels |
| 05/31/2006 | EP1221957B1 Method for preparing a composition by mother-of-pearl extraction,and use thereof in cosmetics and dermatology |
| 05/31/2006 | EP1202719B1 Anesthetic composition for intravenous injection comprising propofol |
| 05/31/2006 | EP1175901B1 Peroxisome activator-responsive receptor agonists |
| 05/31/2006 | EP1175489B1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 05/31/2006 | EP1165110B1 Antagonists of hmg1 for treating inflammatory conditions |
| 05/31/2006 | EP1165073B1 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 05/31/2006 | EP1163238B1 Chemokine recpetor binding heterocyclic compounds |
| 05/31/2006 | EP1161518B1 Towelette product |
| 05/31/2006 | EP1121109B1 Biphasic tramadol preparation |
| 05/31/2006 | EP1112067B1 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes |
| 05/31/2006 | EP1090136B1 Mumbaistatin, a process for its production and its use as a pharmaceutical |
| 05/31/2006 | EP1067908B1 Taxane microemulsions |
| 05/31/2006 | EP1030651A4 Novel oral dosage form for carvedilol |
| 05/31/2006 | EP0994743B1 Treatment of inflammatory disorders of the bowel or urinary bladder |
| 05/31/2006 | EP0946501B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
| 05/31/2006 | EP0885228B1 Meso-substituted tripyrrane compounds, compositions, and methods for making and using the same |
| 05/31/2006 | EP0869775A4 Dietary fiber delivery system |
| 05/31/2006 | EP0861321B1 Phosphopantetheinyl transferases and uses thereof |
| 05/31/2006 | EP0840789B1 Transketolase-related protein |
| 05/31/2006 | EP0839040B1 Use of cgmp-phosphodiesterase inhibitors to treat impotence |
| 05/31/2006 | CN1780922A Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| 05/31/2006 | CN1780919A Methods and products based on oligomerization of stress proteins |